GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo

被引：16
作者：
Jiang, Kaili [1 ]
Tang, Xia [1 ]
Guo, Jing [1 ]
He, Rui [1 ]
Chan, Shingpan [1 ]
Song, Xiaojuan [2 ]
Tu, Zhengchao [1 ,2 ]
Wang, Yuting [1 ]
Ren, Xiaomei [1 ]
Ding, Ke [1 ]
Zhang, Zhang [1 ]
机构：
[1] Jinan Univ, Int Cooperat Lab Tradit Chinese Med Modernizat &, Guangzhou City Key Lab Precis Chem Drug Dev, Chinese Minist Educ MOE,Sch Pharm, Guangzhou, Peoples R China
[2] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou, Peoples R China
来源：
CANCER MEDICINE | 2021年 / 10卷 / 14期
基金：
中国国家自然科学基金;
关键词：
FGFR1; GZD824; resistance; V561F; ACQUIRED-RESISTANCE; INHIBITOR; FGFR1; KINASE; CELL; ACTIVATION; SENSITIVITY; EXPRESSION; MUTATIONS; REVEALS;
D O I：
10.1002/cam4.4041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation, has been reported. To date however, no FGFR inhibitors have beenapproved to treat patients with FGFR mutant resistance. Herein, we report that GZD824, athird generation ABL inhibitor (Phase II, China), overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. GZD824potently suppresses FGFR1/2/3 with an IC50 value of 4.14 +/- 0.96, 2.77 +/- 0.082, and 8.10 +/- 0.15 nmol/L. It effectively overcomes FGFR1-V561F/M and other mutantresistance in Ba/F3 stable cells (IC50:8.1-55.0 nM), and effectively inhibits the growth of Ba/F3-FGFR1-V561F/M mutantxenograft tumors in vivo (TGI=73.4%, 49.8% at20mg/kg, p.o, q2d). GZD824may be considered to be an effective drug to treat patients with FGFR1 abnormalactivation or mutant resistance in clinical trials.
引用
收藏
页码：4874 / 4884
页数：11
相关论文
共 32 条
  • [1] Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer
    Adachi, Yuta
    Watanabe, Kazuyoshi
    Kita, Kenji
    Kitai, Hidenori
    Kotani, Hiroshi
    Sato, Yuki
    Inase, Naohiko
    Yano, Seiji
    Ebi, Hiromichi
    [J]. CARCINOGENESIS, 2017, 38 (11) : 1063 - 1072
  • [2] Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma
    Agelopoulos, Konstantin
    Richter, Guenther H. S.
    Schmidt, Eva
    Dirksen, Uta
    von Heyking, Kristina
    Moser, Benjamin
    Klein, Hans-Ulrich
    Kontny, Udo
    Dugas, Martin
    Poos, Kathrin
    Korsching, Eberhard
    Buch, Thorsten
    Weckesser, Matthias
    Schulze, Isabell
    Besoke, Regina
    Witten, Anika
    Stoll, Monika
    Koehler, Gabriele
    Hartmann, Wolfgang
    Wardelmann, Eva
    Rossig, Claudia
    Baumhoer, Daniel
    Juergens, Heribert
    Burdach, Stefan
    Berdel, Wolfgang E.
    Mueller-Tidow, Carsten
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4935 - 4946
  • [3] Advances and challenges in targeting FGFR signalling in cancer
    Babina, Irina S.
    Turner, Nicholas C.
    [J]. NATURE REVIEWS CANCER, 2017, 17 (05) : 318 - 332
  • [4] E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
    Bello, Ezia
    Colella, Gennaro
    Scarlato, Valentina
    Oliva, Paolo
    Berndt, Alexander
    Valbusa, Giovanni
    Serra, Sonia Colombo
    D'Incalci, Maurizio
    Cavalletti, Ennio
    Giavazzi, Raffaella
    Damia, Giovanna
    Camboni, Gabriella
    [J]. CANCER RESEARCH, 2011, 71 (04) : 1396 - 1405
  • [5] Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand
    D'Angelo, Alberto
    Bagby, Stefan
    Galli, Ilaria Camilla
    Bortoletti, Carlotta
    Roviello, Giandomenico
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (10) : 1139 - 1146
  • [6] Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
    Dai, Shuyan
    Zhou, Zhan
    Chen, Zhuchu
    Xu, Guangyu
    Chen, Yongheng
    [J]. CELLS, 2019, 8 (06)
  • [7] Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
    Datta, Jharna
    Damodaran, Senthilkumar
    Parks, Hannah
    Ocrainiciuc, Cristina
    Miya, Jharna
    Yu, Lianbo
    Gardner, Elijah P.
    Samorodnitsky, Eric
    Wing, Michele R.
    Bhatt, Darshna
    Hays, John
    Reeser, Julie W.
    Roychowdhury, Sameek
    [J]. MOLECULAR CANCER THERAPEUTICS, 2017, 16 (04) : 614 - 624
  • [8] FGFR1 N546K and H3F3A K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers
    Dyson, Kyle
    Rivera-Zengotita, Marie
    Kresak, Jesse
    Weaver, Kristin
    Stover, Brian
    Fort, John
    Rahman, Maryam
    Pincus, David W.
    Sayour, Elias J.
    [J]. HISTOPATHOLOGY, 2016, 69 (04) : 704 - 707
  • [9] FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice
    Ferone, Giustina
    Song, Ji-Ying
    Krijgsman, Oscar
    van der Vliet, Jan
    Cozijnsen, Miranda
    Semenova, Ekaterina A.
    Adams, David J.
    Peeper, Daniel
    Berns, Anton
    [J]. CELL REPORTS, 2020, 30 (11): : 3837 - +
  • [10] AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
    Gavine, Paul R.
    Mooney, Lorraine
    Kilgour, Elaine
    Thomas, Andrew P.
    Al-Kadhimi, Katherine
    Beck, Sarah
    Rooney, Claire
    Coleman, Tanya
    Baker, Dawn
    Mellor, Martine J.
    Brooks, A. Nigel
    Klinowska, Teresa
    [J]. CANCER RESEARCH, 2012, 72 (08) : 2045 - 2056
1234